Stock Trades by Senator Perdue Said to Have Prompted Justice Dept. Inquiry

WASHINGTON — Early this year, Senator David Perdue, Republican of Georgia, sold more than $1 million worth of stock in the financial company Cardlytics, where he once served on the board. Six weeks later, its share price tumbled when the company’s founder announced he would step down as chief executive and the firm said its future sales would be worse than expected.

After the company’s stock price bottomed out in March at $29, Mr. Perdue bought back a substantial portion of the shares that he had sold. They are now trading at around $120 per share.

The Cardlytics transactions drew the attention this spring of investigators at the Justice Department, who were undertaking a broad review of the senator’s prolific trading around the outset of the coronavirus pandemic for possible evidence of insider trading, according to four people with knowledge of the case who described aspects of it on the condition of anonymity. Though Mr. Perdue alluded to the federal inquiry in a campaign ad this fall, its details have not been previously reported.

Investigators found that Cardlytics’ chief executive at the time, Scott Grimes, sent Mr. Perdue a personal email two days before the senator’s stock sale that made a vague mention of “upcoming changes.” The timing of the message prompted additional scrutiny from investigators in both Washington and Atlanta. But ultimately they concluded the exchange contained no meaningful nonpublic information and declined to pursue charges, closing the case this summer.

The federal scrutiny, which also included attention from the Securities and Exchange Commission, is the most vivid example to date of how Mr. Perdue’s complex financial interests and frequent trading have complicated his pursuit of a second Senate term. The results of January’s two Senate runoffs in Georgia, including Mr. Perdue’s race, will determine which party controls the chamber and with it, President-elect Joseph R. Biden Jr.’s ability to advance his agenda through Congress.

Democrats have used details of his trades to accuse Mr. Perdue of lining his pockets when Americans were worried about their jobs and health, and in some cases, leveled corruption charges.

Congress’s ethics rules do not bar lawmakers from holding or trading individual stocks, but like other Americans, they are not allowed to trade on inside information. Other lawmakers have decided it is not worth the political sweat that comes with the appearance of possible conflicts of interest and have steered their investments into diversified mutual funds. But Mr. Perdue, a former executive at Reebok and Dollar General, has been one of the most active traders on Capitol Hill.

A spokesman for Mr. Perdue’s campaign confirmed the investigation in a statement, saying that investigators with the Justice Department and Securities and Exchange Commission “quickly and independently cleared Senator Perdue of any wrongdoing — this story highlights that again.”

“Senator Perdue has always followed the law,” the spokesman, John Burke, said.

A Justice Department spokesman and Securities and Exchange Commission officials did not respond to requests for comment. Representatives for the U.S. attorneys’ offices in Washington and Atlanta and the F.B.I. declined to comment.

A spokesman for Goldman Sachs, which handles Mr. Perdue’s portfolio, said that the bank had “fully cooperated with inquiries” about Mr. Perdue but declined to comment further, citing a policy of not commenting on its clients.

Mr. Grimes and officials at Cardlytics did not respond to requests for comment.

The inquiry into Mr. Perdue roughly coincided with an unusual blitz of federal scrutiny on senators and their financial transactions, but it appears to have taken a somewhat different track.

In the other cases, the Justice Department’s public corruption unit focused on stock sales around the beginning of the coronavirus pandemic, when markets dropped precipitously, by Senators Richard Burr of North Carolina, Dianne Feinstein of California, Jim Inhofe of Oklahoma and Kelly Loeffler of Georgia. Ms. Loeffler is competing in the state’s other runoff election.

Investigators scrutinized whether the senators had dumped stocks and bought others in key sectors after receiving nonpublic briefings on the virus from experts and ahead of the market drop. The cases were closed on all of them except for Mr. Burr.

The investigation into Mr. Perdue appears to have started in a similar fashion, but came to focus more intensely on the Cardlytics transactions.

F.B.I. agents in Washington spoke with Mr. Perdue in June, asking him questions about his financial transactions. The extent of the conversation was unclear, according to two people with knowledge of the conversation.

Mr. Perdue’s lawyers turned over hundreds of pages of information, including the emails with Mr. Grimes, in response to a subpoena from a grand jury.

During the campaign, Mr. Perdue disclosed in a televised ad that a “full review of his stock trades” by the Justice Department and the Securities and Exchange Commission had “cleared him completely,” but made no mention of Cardlytics or the extent of the federal scrutiny.

Mr. Grimes and Mr. Perdue had known each other since at least 2010, when Mr. Perdue joined the board of Cardlytics, then a small and privately held Atlanta start-up. Mr. Perdue resigned his directorship in 2014 after his election to the Senate, but struck an unusual financial arrangement on his way out that paved the way for him to benefit from holding a stake in the company when it went public four years later.

As a senator, Mr. Perdue continued to hold shares of Cardlytics, where executives said he had made valuable contributions to the company, along with scores of other stocks that he traded. In 2019, Mr. Grimes made the maximum donation of $5,600 to Mr. Perdue’s re-election efforts, in what appeared to be his only political contribution of the election cycle.

The email correspondence between the two men began on Jan. 21 and took place just before Mr. Perdue placed the well-timed trades.

“David, I know you are about to do a call with David Evans,” Mr. Grimes wrote from his iPad, according to a copy of the exchange reviewed by The New York Times. “As an FYI, I have not told him about the upcoming changes. Thanks, Scott.”

Mr. Evans, then the chief financial officer of Cardlytics, stepped down from that role six weeks after Mr. Grimes sent the email, at the same time that Mr. Grimes announced plans to assume a new role as executive chairman. Mr. Evans said in July that he was leaving the company.

Mr. Perdue responded to Mr. Grimes’s email by saying he would check with his Senate scheduler but “I don’t know about a call with David or the changes you mentioned.”

Mr. Grimes wrote back the next morning to apologize.

“David, Sorry. That email was not meant for you. Wrong David!” he wrote.

Mr. Perdue then contacted his wealth manager at Goldman Sachs, Robert Hutchinson, and instructed him to sell a little more than $1 million worth of Cardlytics shares, or about 20 percent of his position, three of the people said. One person familiar with the inquiry into Mr. Perdue’s trades said that the conversation was memorialized in an internal Goldman Sachs record later obtained by the F.B.I.

Financial disclosure forms Mr. Perdue is required to file with the Senate show a Jan. 23 sale of $1 million to $5 million in Cardlytics stock.

Investigators in Washington began scrutinizing Mr. Perdue in the spring; by June, the U.S. attorney’s office in Atlanta was handling the case along with prosecutors in the department’s criminal division in Washington.

Mr. Hutchinson told the F.B.I. that Mr. Perdue and his wife weighed in only on broader investing issues, like the proportion of stocks and bonds to hold in their portfolio, according to a person with knowledge of his interview. But a person familiar with the senator’s money-management arrangements with Goldman Sachs said that Mr. Perdue retained some degree of discretion over which trades were made and when.

In this case, Mr. Perdue’s legal team told investigators that Mr. Hutchinson had advised their client in October 2019 that he needed to sell Cardlytics shares to balance his holdings. The shares had increased in value and the advisers argued that Mr. Perdue should take the profits from the sales and reinvest them elsewhere to limit his exposure to the fluctuation of a single stock. Mr. Perdue elected to go forward with those changes in January, his lawyers said.

Mr. Hutchinson declined to comment.

After conducting interviews, including with Mr. Perdue and Mr. Grimes, investigators reached their conclusion that the senator had no nonpublic information about the company’s performance when he made the Cardlytics trade. The investigation was closed later in the summer, according to the people familiar with the case.

If the email from Mr. Grimes was accidental, said Tai Park, a former federal prosecutor and white-collar crime partner at the law firm White & Case, Mr. Perdue “may be on firmer ground, because that’s objective evidence that the C.E.O. was not trying to tip him. In any event, trading on the basis of information learned from a C.E.O. of a company is exceedingly risky under any scenario and could draw attention from investigators.”

All countries
194,555,165
Total confirmed cases
Updated on July 25, 2021 12:02 pm
Italy
4,312,673
Total confirmed cases
Updated on July 25, 2021 12:02 pm
Spain
4,280,429
Total confirmed cases
Updated on July 25, 2021 12:02 pm
Iran
3,691,432
Total confirmed cases
Updated on July 25, 2021 12:02 pm
Germany
3,761,850
Total confirmed cases
Updated on July 25, 2021 12:02 pm

Latest Updates

Without Backpackers to Pick Them, Crops Rot by the Ton in Australia

SHEPPARTON, Australia — Peter Hall ran a hand over the Gala apples sitting in a wooden crate on his orchard in southeastern Australia, lamenting...

U.S. Will Have Enough COVID-19 Vaccines for All Adults by End of May, Biden Says

You have reached your limit of 4 free articles. Get unlimited access to TIME.com.99¢ for the first month Subscribe Now You have...

Biden Vows Enough Vaccine ‘for Every Adult American’ by End of May

But Johnson & Johnson and its partners fell behind in their manufacturing. The company was supposed to deliver its first 37 million doses by...

Popular Articles

Without Backpackers to Pick Them, Crops Rot by the Ton in Australia

SHEPPARTON, Australia — Peter Hall ran a hand over the Gala apples sitting in a wooden crate on his orchard in southeastern Australia, lamenting...

U.S. Will Have Enough COVID-19 Vaccines for All Adults by End of May, Biden Says

You have reached your limit of 4 free articles. Get unlimited access to TIME.com.99¢ for the first month Subscribe Now You have...

Biden Vows Enough Vaccine ‘for Every Adult American’ by End of May

But Johnson & Johnson and its partners fell behind in their manufacturing. The company was supposed to deliver its first 37 million doses by...

Twitch gamer Sodapoppin quits fake GTA jobs because they’re too hard

Sometimes being a fake fast-food restaurant manager can be as taxing as being a real one. This is especially true when you also have pretend...

Sarkozy says could take corruption appeal to European human rights court

France's former president Nicolas Sarkozy said Tuesday that he might consider taking his appeal against a corruption conviction to the European Court of...

Where Biden’s Foreign Policy Is Taking the U.S.

One day before the administration announced its decision on Saudi Arabia, Biden gave the first major indication of his presidency that he would be...

Interviews